Investigational — not yet approved

This treatment is in clinical trials and has not been approved by the FDA or any regulatory authority. It is not available for prescription. Current stage: Phase 3 starting Q1 2026. Estimated approval: 2028+ (estimated — not confirmed) — subject to change.

Amycretin

Novo Nordisk

A single unimolecular drug that activates both GLP-1 and amylin receptors — hitting the same two targets as CagriSema but in a single molecule rather than two separate drugs combined. Both a weekly injection and a daily pill are being developed. Early data shows exceptional promise, with oral Phase 1 results exceeding oral semaglutide.

Quick read · 4 min

In simple terms:
  • •Amycretin is an investigational drug — it has not yet been approved by any regulatory authority
  • •Best trial result so far: up to 22% average weight loss
  • •Current stage: Phase 3 starting Q1 2026
  • •Expected approval: 2028+ (estimated — not confirmed) — this is an estimate and not confirmed

Based on clinical trials · No rankings · Every claim linked to source

Last reviewed: March 2026

up to 22%
best trial result
Phase 3
current stage
2028+ (estimated — not confirmed)
est. approval (not confirmed)
Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.

How it works

A single molecule designed to agonise both GLP-1 receptors (appetite reduction, gastric slowing) and amylin receptors (appetite reduction, gastric slowing via brainstem pathways). The single-molecule approach may simplify manufacturing compared to a fixed-dose combination like CagriSema.

Timeline note: Phase 1 oral data showed significant weight loss within 12 weeks; subcutaneous Phase 2 data over 36 weeks

Early-stage data

Phase 1 and Phase 2 data only. Phase 3 trials are planned but not yet complete. Early results should be interpreted with caution.

Subcutaneous injection20 mg once-weekly · 36 weeks

In trial data, 22% mean weight loss vs. 2% weight gain in placebo (Phase 1b/2a)

Oral tablet2 × 50 mg daily · 12 weeks

In trial data, 13.1% weight loss vs. 1.1% placebo (Phase 1). Compared to oral semaglutide (~6% at same timepoint).

Side effects (early-stage data)

Frequencies from Phase 2 trial data. Final Phase 3 safety profile may differ.

Nausea(40%)
Vomiting(20%)
Diarrhoea(18%)

Notable findings

  • ✓Oral formulation showed 13.1% weight loss in 12 weeks — outperforming oral semaglutide at the same timepoint (6%)
  • ✓Single molecule may be simpler to manufacture than CagriSema's two-drug combination
  • ✓Both injection and pill formulations in development — offering choice

Community insights

These are personal experiences shared in public online communities — not medical advice.

“This is genuinely early — Phase 1 and small Phase 2 data only. The 22% and 13.1% numbers are exciting but from tiny, short studies. Phase 3 will be the real test.”

r/antiobesitymedication·Cautious perspective shared when early data was discussed

Sources & references

  1. [1]
    Phase 1b/2a randomised controlled trial (subcutaneous)
    Adults with overweight or obesity · 36 weeks
    22% mean weight loss at 20 mg subcutaneous vs. ~2% weight gain in placebo. GI safety profile consistent with incretin class.
    Presented at EASD 2024 / Patient Care Online (2024) ↗
  2. [2]
    Phase 1 oral formulation trial
    Adults with overweight or obesity · 12 weeks
    13.1% weight loss at 2×50 mg/day vs. 1.1% placebo — exceeding oral semaglutide results at the same 12-week timepoint (~6%).
    EASD 2024 annual meeting / Patient Care Online (2024) ↗

Next step most people take

See what's available today
FDA-approved prescription treatments you can get now
How GLP-1 drugs work
Plain English explanation of the underlying mechanism
Compare all options
See all treatment types side by side